Advanced Filters
noise

Lappersdorf, Germany Clinical Trials

A listing of Lappersdorf, Germany clinical trials actively recruiting patients volunteers.

Found 74 clinical trials
R Rosa Klotz, MD

Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas

This is an interventional, open-label, non-randomised, multicentre, single-arm phase II clinical trial. Eligible patients with hepatic oligometastatic adenocarcinoma of the pancreas will receive neoadjuvant combination chemotherapy (liposomal irinotecan, oxaliplatin, 5-fluouracil, folinic acid (NAPOX)) in cycles of 14 days. Patients with tumour response or stable disease and a resectable primary tumour …

18 years of age All Phase 2
S Selim Corbacioglu, MD

A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD

HSCT is currently the only curative option for SCD but less than 20% of SCD patients have a MD donor available. So far, all curative approaches beyond a MSD HSCT at young age are non-satisfactory. With the lack of a suitable donor for the vast majority of patients, the major …

2 - 35 years of age All Phase 2
S Sterzing, Prof. Dr.

Fractionated Stereotactic Radiotherapy vs. Single Session Radiosurgery in Patients With Larger Brain Metastases

Phase III trial comparing local control and side effects after fractionated stereotactic radiotherapy and single session radiosurgery in patients with larger brain metastases (2-4 cm)

18 years of age All Phase 3

Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients

This clinical phase II study is designed to investigate the efficacy of intratumorally administered L19IL2/L19TNF in patients with injectable lesions of BCC or cSCC. Favorable tumor responses following intralesional treatment with L19IL2/L19TNF have been observed in patients with injectable melanoma lesions of stage III or IV, for injected and non-injected …

18 - 100 years of age All Phase 2

Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)

This phase I/II clinical trial evaluates the safety and efficacy of the combined administration of midostaurin and gemtuzumab ozogamicin in the frame of first-line standard chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients displaying a cytogenetic aberration or fusion transcript in the core-binding factor (CBF) genes or FMS-like tyrosine …

18 - 75 years of age All Phase 1/2

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors

Primary objective: To determine the maximum tolerated dose and/or recommended dose for extension for IMA401 Secondary objectives: To characterize the safety and tolerability of IMA401 To evaluate initial anti-tumor activity of IMA401 To describe the pharmacokinetics of IMA401

18 years of age All Phase 1
U Ursula Nestle, MD

Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody

The MIR study proved the effect of Rituximab in combination with a localized irradiation given in a standard dose. Together with the TROG 99.03 trial, this led to the recommendation of using this combined approach in early stage nodal follicular lymphoma. The GAZAI study is currently looking for the effect …

18 years of age All Phase 3
B Berthold Langguth

Intermittent Theta Burst Stimulation for Maintenance Therapy in Depression

This is a randomized, multi-center, open-label study in which patients with depression who responded to an open-label treatment with intermittent theta burst stimulation (iTBS) will receive this procedure as maintenance therapy. The patients will be randomized to two study arms. The arms differ in the frequency of stimulation (standard iTBS …

18 - 70 years of age All Phase N/A

Fight INflammation to Improve Outcome After Aneurysmal Subarachnoid HEmorRhage

Aneurysmal subarachnoid hemorrhage (SAH) is a fatal disease with high morbidity and mortality. While the primary injury results from the initial bleeding and cannot be influenced, secondary injury through vasospasms and delayed cerebral ischemia (DCI) during the course of the disease might be a target for intervention in order to …

18 years of age All Phase 3

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors. Primary objectives: To determine the maximum tolerated dose and/or recommended dose for extension for IMA402 (Phase I) To characterize the safety and tolerability of IMA402 …

18 years of age All Phase 1/2

Simplify language using AI